0001850051 false 0001850051 2021-12-23 2021-12-23 0001850051 iqmdu:UnitsEachConsistingOfOneShareOfClassACommonStockDollar0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2021-12-23 2021-12-23 0001850051 us-gaap:CommonClassAMember 2021-12-23 2021-12-23 0001850051 iqmdu:RedeemableWarrantsIncludedAsPartOfTheUnitsEachWholeWarrantExercisableForOneShareOfClassACommonStockAtAnExercisePriceOfDollar11.50PerShareMember 2021-12-23 2021-12-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 23, 2021

 

 

INTELLIGENT MEDICINE ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware 001-41024 86-2283527
(State or other jurisdiction of
incorporation or organization)   		(Commission
File Number)   		(I.R.S. Employer
Identification Number)  

 

9001 Burdette Rd.    
Bethesda, MD   20817
(Address of principal executive offices)   (Zip Code)

 

(202) 905-5834

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class   Trading
Symbol(s) 		  Name of each exchange on
which registered
Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-half of one redeemable warrant   IQMDU   The Nasdaq Stock Market LLC
         
Shares of Class A common stock, included as part of the units   IQMD   The Nasdaq Stock Market LLC
         
Redeemable warrants included as part of the units, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share   IQMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

     

 

 

Item 8.01. Other Events.

 

On December 23, 2021, Intelligent Medicine Acquisition Corp. (the “Company”) announced that the holders of the units sold in the Company’s initial public offering (the “Units”) may elect to separately trade the shares of Class A common stock, par value $0.0001 per share (the “Class A common stock”), and redeemable warrants included in the Units commencing on December 27, 2021. Each Unit consists of one share of Class A common stock and one-half of one redeemable warrant to purchase one share of Class A common stock. Any Units not separated will continue to trade on the Nasdaq Global Market (“Nasdaq”) under the symbol “IQMDU”. Any underlying shares of Class A common stock and warrants that are separated will trade on Nasdaq under the symbols “IQMD” and “IQMDW”, respectively. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the holders’ Units into Class A common stock and warrants.

 

A copy of the press release issued by the Company announcing the separate trading of the securities underlying the Units is attached hereto as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1 Press Release dated December 23, 2021

 

     

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 23, 2021

 

  INTELLIGENT MEDICINE ACQUISITION CORP.
     
  By: /s/ Gregory C. Simon
  Name: Gregory C. Simon
  Title: Chief Executive Officer and Chief Financial Officer

 

     

 

Intelligent Medicine Acq... (NASDAQ:IQMDU)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Intelligent Medicine Acq....
Intelligent Medicine Acq... (NASDAQ:IQMDU)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Intelligent Medicine Acq....